Sign In
Buy AGEN
$6.12
+2.77 (+82.69%)
At Close: Jul 13, 2026
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
03:10pm, Monday, 13'th Jul 2026
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
Agenus shares surge as company secures up to $340M to advance colon cancer trial
01:11pm, Monday, 13'th Jul 2026
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its b
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
10:28am, Monday, 13'th Jul 2026
Agenus Inc. (NASDAQ:AGEN) stock surged over 100% in intraday trading on Monday after the immuno-oncology company unveiled an $85 million private placement that could grow to $340 million if investors
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
10:02am, Monday, 13'th Jul 2026
Agenus NASDAQ: AGEN said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk
Agenus shares surge as company secures up to $340M to advance colon cancer trial
08:53am, Monday, 13'th Jul 2026
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to...
VivoPower earns Outperform rating as Noble bets on "power-first" AI strategy
07:00am, Monday, 13'th Jul 2026
VivoPower PLC (NASDAQ:VIVO, FRA:51J)’s pivot toward acquiring and developing power-secured land and powered-shell data center infrastructure has earned it...
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a pri
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study of botensilimab (B
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves
12:08pm, Tuesday, 16'th Jun 2026
Agenus NASDAQ: AGEN told shareholders at its 2026 virtual annual meeting that it remains focused on advancing its botensilimab and balstilimab immunotherapy combination, known as BOT/BAL, while workin
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
12:31pm, Wednesday, 10'th Jun 2026
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock?
AGEN Early Access Revenues Signal a New Path Ahead of Approval
03:05pm, Friday, 05'th Jun 2026
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
03:02pm, Friday, 05'th Jun 2026
AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
02:55pm, Friday, 05'th Jun 2026
Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.
